Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 813-822

  Murugesan, Selva R ^a   Akiyama, Masaki ^b   Einfeld, David A ^a   Wickham, Thomas J ^a,c   King, C Richter ^a  

^a GENVEC INC   (United States)

^b Fuso Pharmaceutical Industries Ltd   (Japan)

^c EMD SERONO INC   (United States)

Author keywords

Adenovirus vector; Gene therapy; Human ovarian cancer; MUC 1 DF3; RGD 4C; Tumor necrosis factor

Indexed keywords

ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; LUCIFERASE; OLIGOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; FEMALE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NUDE MOUSE; OVARY TUMOR; PERITONEUM TUMOR; PROMOTER REGION; SURVIVAL RATE; VIRUS CAPSID;

ADENOVIRIDAE; ANIMALS; CAPSID; FEMALE; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTEGRIN ALPHAVBETA3; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROMOTER REGIONS (GENETICS); SURVIVAL RATE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35848961674     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.813     Document Type: Article

References (56)

1. American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 2007.
2. McCreath WA and Chi DS: Surgical cytoreduction in ovarian cancer. Oncology 18: 645-653, 2004.
3. Bookman MA, McGuire WP, Kilpatrick D, et al: Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14: 1895-1902, 1996.
4. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
5. Zeimet AG and Marth C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4: 415-422, 2003.
6. See HT and Kavanagh JJ: Novel agents in epithelial ovarian cancer. Cancer Invest 22: 29-44, 2004. (Pubitemid 40065218)
7. Raki M, Rein DT, Kanerva A and Hemminki A: Gene transfer approaches for gynecological diseases. Mol Ther 14: 154-163, 2006. (Pubitemid 43942349)
8. Rocconi RP, Numnum TM, Stoff-Khalili M, Makhija S, Alvarez RD and Curiel DT: Targeted gene therapy for ovarian cancer. Curr Gene Ther 5: 643-653, 2005. (Pubitemid 43009508)
9. Wolf JK and Jenkins AD: Gene therapy for ovarian cancer (Review). Int J Oncol 21: 461-468, 2002.
10. Buller RE, Runnebaum IB, Karlan BY, et al: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9: 553-566, 2002. (Pubitemid 34734419)
11. Alvarez RD, Barnes MN, Gomez-Navarro J, et al: A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6: 3081-3087, 2000. (Pubitemid 30637731)
12. Hasenburg A, Tong XW, Fischer DC, et al: Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 83: 549-554, 2001. (Pubitemid 33139718)
13. Alvarez RD and Curiel DT: A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther 8: 597-613, 1997.
14. Mahasreshti PJ, Kataram M, Wu H, et al: Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol 100: 521-532, 2006.
15. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996.
16. McDermott MF: TNF and TNFR biology in health and disease. Cell Mol Biol 47: 619-635, 2001.
17. Mueller H: Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 54: 1291-1298, 1998.
18. Grunhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH and Eggermont AM: TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 120: 65-79, 2004.
19. Weichselbaum RR, Kufe DW, Hellman S, et al: Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 3: 665-671, 2002.
20. Sharma A, Mani S, Hanna N, et al: Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 12: 1109-1131, 2001.
21. Senzer N, Mani S, Rosemurgy A, et al: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22: 592-601, 2004.
22. Wickham TJ: Ligand-directed targeting of genes to the site of disease. Nat Med 9: 135-139, 2003.
23. Bergelson J, Cunningham J, Droguett G, et al: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997.
24. Kirby I, Davison E, Beavil AJ, et al: Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 73: 9508-9514, 1999.
25. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I and Wickham TJ: Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286: 1568-1571, 1999.
26. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319, 1993.
27. Wickham TJ, Carrion ME and Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 2: 750-756, 1995.
28. Zeimet AG, Muller-Holzner E, Schuler A, et al: Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 9: 1093-1100, 2002.
29. Kelly FJ, Miller CR, Buchsbaum DJ, et al: Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 6: 4323-4333, 2000.
30. Lo HW, Day CP and Hung MC: Cancer-specific gene therapy. Adv Genet 54: 235-255, 2005.
31. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H and Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223-232, 1984.
32. Finn OJ, Jerome KR, Henderson RA, et al: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 45: 61-89, 1995.
33. Tai YT, Strobel T, Kufe D and Cannistra SA: In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 59: 2121-2126, 1999.
34. Feng H, Ghazizadeh M, Konishi H and Araki T: Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32: 525-529, 2002.
35. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP and Amin KM: An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 62: 3438-3447, 2002.
36. Parr MJ, Manome Y, Tanaka T, et al: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3: 1145-1149, 1997.
37. Gu J, Andreeff M, Roth JA and Fang B: hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9: 30-37, 2002.
38. Kanerva A, Bauerschmitz GJ, Yamamoto M, et al: A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 11: 552-559, 2004.
39. Kurihara T, Brough DE, Kovesdi I and Kufe DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106: 763-771, 2000.
40. Bauerschmitz GJ, Guse K, Kanerva A, et al: Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 14: 164-174, 2006.
41. Brough DE, Lizonova A, Hsu C, Kulesa VA and Kovesdi I: A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70: 6497-6501, 1996. (Pubitemid 26266881)
42. Rasmussen H, Rasmussen C, Lempicki M, et al: TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9: 951-957, 2002. (Pubitemid 35278568)
43. Einfeld DA, Schroeder R, Roelvink PW, et al: Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75: 11284-11291, 2001. (Pubitemid 33063218)
44. Akiyama M, Thorne S, Kirn D, et al: Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 9: 218-230, 2004. (Pubitemid 38256548)
45. Wu S, Boyer CM, Whitaker RS, et al: Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53: 1939-1944, 1993.
46. Kulbe H, Thompson R, Wilson JL, et al: The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585-592, 2007. (Pubitemid 46192196)
47. Pikarsky E, Porat RM, Stein I, et al: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466, 2004. (Pubitemid 39329586)
48. Hemminki A, Belousova N, Zinn KR, et al: An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 4: 223-231, 2001.
49. Dmitriev I, Krasnykh V, Miller CR, et al: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706-9713, 1998.
50. Liapis H, Adler LM, Wick MR and Rader JS: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 28: 443-449, 1997. (Pubitemid 27175085)
51. Witz CA, Montoya-Rodriguez IA, Miller DM, Schneider BG and Schenken RS: Mesothelium expression of integrins in vivo and in vitro. J Soc Gynecol Investig 5: 87-93, 1998.
52. Vanderkwaak TJ, Wang M, Gomez-Navarro J, et al: An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 74: 227-234, 1999. (Pubitemid 29377217)
53. Chen L, Cheng DS, Manome Y, Dong YH, Fine HA and Kufe DW: Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 96: 2775-2782, 1995.
54. Rein DT, Breidenbach M, Kirby TO, et al: A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11: 1327-1335, 2005.
55. Wu H, Han T, Lam JT, et al: Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther 11: 874-878, 2004. (Pubitemid 38714591)
56. Wang M, Hemminki A, Siegal GP, et al: Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 96: 341-348, 2005. (Pubitemid 40127132)